Ophthalmic co Wize Pharma signs China distribution deal

Eye Photo: Intel

Wize sees up to $40 million in sales in China over five years for LO2A for the treatment of dry eye syndrome (DES), and other ophthalmological illnesses.

Israeli ophthalmic treatment developer Wize Pharma Inc. (OTCQB: WIZP) announced that it has signed an exclusive distribution agreement in China with HPGC Medical Co. Ltd. (HPGC) for LO2A, a drug developed for the treatment of dry eye syndrome (DES), and other ophthalmological illnesses, including Conjunctivochalasis (CCH) and Sjögren's syndrome (Sjögren's). HPGC is a division of Harbin Pharmaceutical Group Co. Ltd., one of China's largest healthcare companies with 20,000 employees and assets worth $2.9 billion.

Wize Pharma is a clinical-stage biopharmaceutical company based in Hod Hasharon north of Tel Aviv, which is focused on the treatment of ophthalmic disorders.

Under the terms of the agreement, Wize has granted HPGC exclusive rights to distribute LO2A in China for treating DES, CCH, and Sjögren's. HPGC is responsible for obtaining regulatory approval for LO2A in China, as well as all costs associated with clinical trials, if needed, and registration fees.

The agreement includes minimum quantities of LO2A to be purchased by HPGC from Wize, after obtaining the necessary regulatory approvals in China. Based on quantities outlined in the agreement, Wize expects between $22.5 million and $40 million in sales in China over five years following receipt of the necessary regulatory approvals in China. However, Wize stresses that there is no guarantee that such approval will be obtained.

Wize chairman Ron Mayron said,"We are very pleased to enter this agreement with HPGC, a leading pharmaceutical company in China. We have established a firm timeline for milestones around regulatory approval and expect regulatory clearance in China in the next year-and-a-half. Upon approval, HPGC's distribution channels will deliver LO2A to a substantial national market. We are pleased to partner with HPGC to deliver an effective and safe dry eye product in China."

The ophthalmology market in China is growing at a CAGR of over 11% and is expected to reach $4.5 billion in 2023, according to Market Scope.

Published by Globes [online], Israel business news - www.globes-online.com - on June 6, 2018

© Copyright of Globes Publisher Itonut (1983) Ltd. 2018

View comments in rows
Update by email about comments talkback
Eye Photo: Intel
Eye Photo: Intel
Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018